Many of the voltage-gated potassium channels (K~V~1--12) are expressed in the central nervous system (CNS), playing an important role in neuronal excitability and neurotransmitter release^[@R7]^. Mutations in potassium channel-encoding genes cause different neurological diseases, including benign familial neonatal seizures (*KCNQ2*/K~V~7.2, *KCNQ3*/K~V~7.3)^[@R8]-[@R10]^, neonatal epileptic encephalopathy (*KCNQ2*)^[@R11],[@R12]^, episodic ataxia type 1 (EA1) (*KCNA1*/K~V~1.1)^[@R13]^, and peripheral nerve hyperexcitability (*KCNA1*, *KCNQ2*)^[@R13]-[@R15]^. In addition, antibodies against K~V~1.1 or associated proteins like Contactin-associated protein 2 (Caspr2) or Leucine-rich, glioma-inactivated 1 protein (LGI1) cause limbic encephalitis or neuromyotonia^[@R16]^. Therefore, potassium channel genes represent interesting candidates for neurodevelopmental disorders.

To identify mutations in presumed genetic forms of epilepsy, we designed a targeted re-sequencing panel^[@R17]^ comprising 265 known and 220 candidate genes for epilepsy ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}). Screening a pilot cohort of 33 patients, we identified mutations in known epilepsy genes in 16 cases^[@R17]^. The remaining 17 cases were evaluated for mutations in candidate genes ([Supplementary note](#SD1){ref-type="supplementary-material"}), which led to the detection of a heterozygous *de novo* mutation in *KCNA2*, c.1214C\>T, p.Pro405Leu (P405L), affecting the highly-conserved pore domain of the voltage-gated potassium channel K~V~1.2. This mutation is not found in control databases (1000G, EVS, dbSNP138, ExAC).

The female Patient \#1 carrying this mutation had unremarkable early development until epilepsy onset at 17 months old. The phenotype included febrile and afebrile alternating hemiclonic seizures and status epilepticus, reminiscent of Dravet syndrome. The electroencephalogram (EEG) showed multifocal spikes with marked activation during sleep. After seizure onset, ataxia and delay of psychomotor and language development became apparent. She had postnatal short stature, growth hormone deficiency and hypothyroidism. Seizures and ataxia responded poorly to antiepileptic drugs (topiramate, oxcarbazepine, valproic acid, bromide), including acetazolamide (known to be effective in EA1 caused by mutations in *KCNA1*^[@R18]^). At last follow-up at eight years old, she had remained seizure-free for the past six months without previous change of medication.

Further *KCNA2* mutations were identified in several parallel studies ([Supplementary Fig. 1](#SD5){ref-type="supplementary-material"}). First, we performed whole exome sequencing (WES) in 86 parent-offspring trios with epileptic encephalopathy (31 with *SCN1A*-negative Dravet syndrome \[DS\], 39 with myoclonic-atonic epilepsy \[MAE\], and 16 with electrical status epilepticus in slow-wave sleep \[ESES\]). Second, we performed panel sequencing ([Supplemental note](#SD1){ref-type="supplementary-material"}) in 147 adult patients with a broad spectrum of epilepsy phenotypes associated with intellectual disability. Third, we performed WES in an adult cohort of 10 independent trios with severe epilepsy and intellectual disability, and WES in another cohort of 12 independent, isolated index cases with early-onset ataxia and epilepsy. We identified six additional independent cases with previously-unreported heterozygous *KCNA2* variants ([Table 1](#T1){ref-type="table"}, [Supplementary note](#SD1){ref-type="supplementary-material"}): Patient \#2 (initially classified as MAE) carried the *de novo* mutation c.788T\>C, p.Ile263Thr (I263T). Patient \#3 (intellectual disability with neonatal-onset focal epilepsy and cerebellar hypoplasia) carried the variant c.440G\>A, p.Arg147Lys (R147K), of unknown inheritance. Since (i) it could not be confirmed as *de novo*, (ii) was predicted as benign from seven out of nine prediction tools, (iii) lysine occurs naturally at that position in drosophila and zebrafish, and (iv) did not reveal functional consequences, R147K was considered a variant of unknown significance (see [Supplementary note](#SM){ref-type="supplementary-material"}, [Supplementary Tables 1](#SD3){ref-type="supplementary-material"} and [2](#SD4){ref-type="supplementary-material"}, and [Supplementary Fig. 3](#SD7){ref-type="supplementary-material"}). Patients \#4 (initially classified as DS with prominent focal seizures) and \#5 (intellectual disability with febrile seizures, focal seizures and status epilepticus) also carried the *de novo* P405L mutation ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 2](#SD6){ref-type="supplementary-material"}). Patients \#1, \#2, \#4 and \#5 eventually became seizure-free between four and 15 years old, whereas intellectual disability and (in \#1 and \#4) mild to moderate ataxia remained unchanged. Recurrence of P405L in three independent cases suggests a mutational hotspot: c.1214 is located in a stretch of cytosines and guanines and the C\>T mutation likely occurs due to a methylated CpG sequence, possibly bypassing the DNA repair system and so becoming prone to this pyrimidine-pyrimidine substitution.

Patient \#6 carried the *de novo* mutation c.894G\>T, p.Leu298Phe (L298F). His phenotype was different and much more severe, presenting with severe intellectual disability with gradual loss of language and motor skills, pharmacoresistant generalized tonic-clonic, atypical absence and myoclonic seizures, facial dysmorphism, generalized epileptic discharges and moderate ataxia ([Table 1](#T1){ref-type="table"} and [Supplementary note](#SD1){ref-type="supplementary-material"}). Similarly, patient \#7 carrying the *de novo* mutation c.890G\>A, p.Arg297Gln (R297Q) presented with a more severe phenotype consisting of moderate intellectual disability, moderate to severe ataxia and pharmacoresistant seizures.

We subsequently screened a follow-up cohort of 99 patients, comprising 47 individuals with unresolved epileptic encephalopathy, short stature and/or ataxia as well as 52 individuals with intellectual disability and idiopathic severe GH deficiency without detecting additional sequence alterations by Sanger sequencing. We excluded copy number variations affecting *KCNA2* in all 99 follow-up cases as well as 86 trio-WES cases using an in-house-developed multiplex amplicon quantification technique (Online Methods and [Supplementary Fig. 1](#SD5){ref-type="supplementary-material"}).

To validate our findings statistically and corroborate *KCNA2* as a new disease-predisposing gene for epileptic encephalopathy, we calculated the probability for recurring *KCNA2* mutations occurring by chance in our cohorts. Comparing the allele frequency of six (two times P405L) *KCNA2* non-synonymous variants in our validation cohorts (6/(354×2), excluding the first P405L mutation detected in the discovery cohort of 33 patients) with those missense and nonsense variants reported in the largest available control database (ExAC, 144/122828), revealed a significant enrichment of *KCNA2* variants in our patient cohorts using Fisher's exact test (p=2.6×10^−4^). Further statistical evidence is provided in the [Supplementary Note](#SD1){ref-type="supplementary-material"}. *KCNA2* had not been associated with a human disease so far. However, during the review process of this manuscript, a single case report was published describing a 7-year-old boy with the *KCNA2 de novo* mutation R297Q presenting with ataxia and myoclonic epilepsy, similar to our patient \#7.^[@R19]^ In addition, the *Pingu* mouse presenting with ataxia and growth retardation carries a *Kcna2* loss-of-function mutation, p.Ile402Thr, in close proximity to P405L; *Kcna2* knock-out mice present with severe seizures and premature death^[@R20],[@R21]^.

K~V~1.2 belongs to the K~V~1 family (K~V~1.1--8), all members of which are expressed in the CNS. These channels consist of four subunits with six transmembrane segments (S1-S6). S4 forms the voltage-sensor and S5-S6 the pore region containing a selectivity filter and gating ion flow^[@R22]^ ([Fig. 1a](#F1){ref-type="fig"}). All four *KCNA2* sequence alterations detected in patients \#1--7 (except the one in \#3) are localized in highly-conserved and functionally-important protein regions ([Fig. 1b](#F1){ref-type="fig"}), and were predicted as pathogenic. P405L disrupts the highly-conserved, K~V~-specific PVP motif in S6, which is thought to link the gate to the voltage-sensor^[@R23],[@R24]^. A PVP\>AVP mutation in K~V~1.5 leads to a non-functional channel^[@R25]^. I263T in S3 may disrupt a hydrophobic segment proposed to focus the electric field across the cell membrane, thus enabling the S4 gating charges to translocate over a smaller distance rather than the entire depth of the membrane bilayer^[@R26]^. Furthermore, I263T in K~V~1.2 corresponds to I262T in K~V~1.1 causing EA1 with distal weakness.^[@R27]^ Finally, R297Q and L298F directly affect the S4 voltage sensor, and R297Q has been described before to induce a negative shift of the activation curve.^[@R27],[@R28]^

Functional effects of all detected sequence alterations were examined using an automated two-microelectrode voltage-clamp oocyte testing system. We found a sigmoidal relationship between the amount of injected wildtype (WT) cRNA and potassium current amplitude, with a strong decrease in amplitude for the 8-fold cRNA amount ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. 5](#SD9){ref-type="supplementary-material"}). This quantitative titration of protein levels by varying the amounts of injected RNA was used to determine the amount of injected cRNA for further experiments. For P405L and I263T, we found a dramatic reduction of current amplitudes and thus a clear loss of channel function ([Figs. 2c](#F2){ref-type="fig"}). When either of the two mutations were co-expressed with WT K~V~1.2 in a 1:1, 1:2 or 1:4 ratio, with constant amount of injected WT cRNA, current amplitudes significantly decreased ([Figs. 2d](#F2){ref-type="fig"}) compared with similar amounts of WT alone ([Fig. 2b](#F2){ref-type="fig"}). Hence, both P405L and I263T exert a clear dominant-negative effect on WT K~V~1.2 channels. Furthermore, I263T caused a depolarizing shift of voltage-dependent activation, and slight changes in inactivation were found for P405L ([Supplementary Fig. 4](#SD8){ref-type="supplementary-material"}).

In contrast to P405L and I263T, both R297Q and L298F induced strong gain-of-function effects. Neutralization of the second arginine in the voltage sensor in K~V~1.2-R297Q increased current amplitudes by 9-fold and shifted the voltage dependence of steady-state activation by −40 mV compared with WT ([Fig. 3a--c](#F3){ref-type="fig"}), The gain-of-function of the L298F mutation was even more pronounced with a 13-fold increase in current amplitudes and a −50 mV shift of the activation curve ([Fig. 3a--c](#F3){ref-type="fig"}). As a consequence of the permanently open mutant channels, resting membrane potentials of oocytes expressing R297Q or L298F channels were about 40 mV more negative than of those expressing WT ([Fig. 3d](#F3){ref-type="fig"}). Both mutations exerted a dominant effect on the WT, since co-injection of either R297Q or L298F with WT in a 0.5:0.5 ratio revealed very similar alterations as with one of the mutations (1.0) alone ([Fig. 3b--d](#F3){ref-type="fig"}).

To examine protein production and stability, we performed SDS-page analysis of total cell lysates using a monoclonal anti-K~V~1.2 antibody. Representative Western blots show that all mutations generate a protein expression level similar to the 57-kD band of the WT ([Figs. 2e](#F2){ref-type="fig"} and [3e](#F3){ref-type="fig"}). A slight but reproducible shift was found for the band of P405L in both oocytes and mammalian cells ([Fig. 2e](#F2){ref-type="fig"}, top, middle). Steric properties of proline can disrupt secondary structure elements, which could be important for the function of the conserved PVP motif. A leucine in this position (LVP) could induce a structural change resulting in altered gel migration^[@R28]^.

K~V~1.2 belongs to the delayed rectifier class of potassium channels enabling efficient neuronal repolarization following an action potential. Loss-of-function mutations predict hyperexcitable neuronal membranes and repetitive neuronal firing due to impaired repolarization. This hypothesis is corroborated by the epileptic phenotype of the *Kcna2* knock-out mouse^[@R21]^. In stark contrast, R297Q and L298F predict permanently open channels at physiological membrane potentials, and electrical silencing by membrane hyperpolarization (as observed in oocytes). It is difficult to speculate about the pathophysiological consequences of a K~V~1.2 loss- or gain-of-function beyond the level of single neurons, particularly since this channel has been detected in a broad range of both excitatory and inhibitory neurons^[@R29],[@R30]^. Further experiments in gene-targeted mouse models could answer these questions.

In summary, we identified *de novo* mutations in *KCNA2* causing mild to severe epileptic encephalopathy in roughly 1.7% of cases across our different cohorts. The phenotype associated with dominant-negative loss-of-function mutations comprised infantile/early-childhood seizure onset, frequent febrile and afebrile focal motor and dyscognitive seizures with overlap to DS (\#1, \#4, \#5) and MAE (\#2). However, focal seizures are uncommon in these syndromes and in particular the observed multifocal epileptiform discharges with marked activation during sleep are not described either in DS or MAE. All four patients became seizure-free between four and 15 years old with no apparent association to a recent change of medication. Thus, this improvement might either be due to a cumulative treatment response or simply represent a spontaneous resolution ([Table 1](#T1){ref-type="table"}, [Supplementary note](#SD1){ref-type="supplementary-material"}). Initially normal psychomotor development slowed after seizure onset, resulting in mild-moderate intellectual disability associated with mild-moderate ataxia and continuous myoclonus in some cases. By contrast, the phenotypes of patients \#6 and \#7, carrying mutations with dominant gain-of-function, were more severe in terms of epilepsy, ataxia and intellectual disability, and also differed electrographically, with generalized epileptic discharges. This may suggest that different pathomechanisms underlie distinctive clinical symptoms. Clinical-genetic studies and correlation with functional investigations from additional patients with further mutations are needed to confirm this genotype-phenotype relationship.

Online Methods {#S1}
==============

Whole exome and panel sequencing analysis {#S2}
-----------------------------------------

High throughput sequencing has been performed as described previously by our group for whole exome analysis^[@R31]^ and panel analysis^[@R17]^.

The panel used to screen the pilot cohort of 33 patients (including the index patient) comprised 485 known and putative epilepsy genes. ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}) The candidates comprised genes that were suggestive for being involved in epileptogenesis due to several reasons, e.g. genes belong to neurotransmitter receptor families or other ion channels, genes were discussed by different research groups as putatively involved in epilepsy, genes are associated with seizures in animals or associated with human neurodevelopmental phenotypes, etc. The gene panel used to screen the second cohort of 147 patients was an updated version of the initial panel. To improve sequence coverage and adapting the panel for purely diagnostic purposes, we excluded a few metabolic and mitochondrial genes as well as most candidate genes and added all recently published novel epileptic encephalopathy genes. This panel finally contained 280 genes including 20 candidates for research settings ([Supplementary Table 2](#SD4){ref-type="supplementary-material"}).

Sanger sequencing analysis and CNV analysis {#S3}
-------------------------------------------

We performed bidirectional Sanger sequencing of all three exons of *KCNA2* (ENST00000485317, NM_004974) and its intron-exon boundaries using the BigDye Terminator v3.1 Cycle Sequencing kit on an ABI3730XL DNA Analyzer (Applied Biosystems, Foster City, CA; primers available upon request) in 47 patients with epileptic encephalopathy and ataxia and/or short stature as well as 52 patients with intellectual disability and severe growth hormone deficiency.

Additionally, the genomic region containing *KCNA2* was screened for CNVs by use of an in-house-developed technique for multiplex amplicon quantification (MAQ). With this MAQ technique, we screened all 99 individuals of the Sanger sequencing cohort as well as all 86 individuals of the WES cohort ([Supplementary Fig. 1](#SD5){ref-type="supplementary-material"}). This assay comprises a multiplex PCR amplification of fluorescently-labeled target and reference amplicons, followed by fragment analysis on the ABI3730 DNA Analyzer^[@R32]^. The comparison of normalized peak areas between the test individual and the average of seven control individuals results in the target amplicon doses indicating the copy number of the target amplicon (using the in-house developed Multiplex Amplicon Quantification Software. The multiplex PCR reaction consists of three test amplicons located in the genomic region of *KCNA2* and three reference amplicons located on different chromosomes (primer mix is available upon request).

### Pathogenicity prediction {#S4}

For the prediction of the pathogenicity of nonsynonymous variants we used the ANNOVAR^[@R33]^ table_annovar.pl script together with the LJB23 database (dbNSFP)^[@R34]^ from June 2013 comprising prediction scores from SIFT, Polyphen2 (HDIV and HVAR), LRT, MutationTaster, MutationAssessor, FATHMM, MetaSVM and MetaLR scores. Scores were used as given on the ANNOVAR webpage. Additional three conservation scores (GERP+, PhyloP, SiPhy) were used to determine the conservation of a genomic position (More details in [Supplementary Table 2](#SD4){ref-type="supplementary-material"}).

### Testing the enrichment of pathogenic variants {#S5}

To test the enrichment of probably damaging nonsynonymous *KCNA2* variants in our data, we used the Exome Aggregation Consortium (ExAC) database as a control dataset. It comprises data from 61,486 individuals coming from various exome sequencing projects including control cohorts data but also data from studies on neurological disorders like schizophrenia and bipolar disorder. We extracted all 64 nonsynonymous (missense and nonsense) variants for *KCNA2* from ExAC \[11/2014\]. Some of them occurred in more than one individual yielding altogether 144 alleles with variation in *KCNA2* out of a total number of 122828 alleles in the ExAC database. Significant enrichment of nonsynonymous variants was then tested determining the difference of allele counts in our data and the ExAC dataset using Fisher's exact test.

Probability assessment of *de novo* mutation events {#S6}
---------------------------------------------------

We first obtained an estimate for the single-nucleotide mutation rate in the *KCNA2* gene. This rate equals the product of the average *de novo* mutation rate in humans of 1.2×10^−8^ per nucleotide per generation^[@R35]^ and the length of the largest coding sequence of *KCNA2* (coding ID in CCDS database: 827.1) of 1,500 base pairs, yielding 1.8×10^−5^ per generation. The probability of observing a *de novo* mutation in *KCNA2* in *k* out of *n* parent-offspring trios then simply follows a binomial distribution with a success probability equaling the gene-based mutation rate, Bin(*n*, *k*, 1.8×10^−5^).

Functional investigations {#S7}
-------------------------

### Mutagenesis and RNA preparation {#S8}

Site-directed mutagenesis was performed to engineer the mutations into the human *KCNA2* cDNA using Quickchange™ (Agilent Technologies, USA; primers are available upon request). The mutant cDNA was fully resequenced before being used in experiments to confirm the introduced mutation and exclude any additional sequence alterations. cRNA was prepared using the SP6 mMessage kit from Ambion. The human K~V~1.2 in the pcDNA3.1 vector was kindly provided by Stephan Grissmer (Institute of Applied Physiology, Ulm University).

### Electrophysiology {#S9}

*Xenopus laevis* oocytes were obtained from the Institute of Physiology I, Tübingen. Preparation of the oocytes was performed as described previously^[@R12]^. Oocytes were treated with collagenase (1 mg/ml of type CLS II collagenase, Biochrom KG) in OR-2 solution (in mM: 82.5 NaCl, 2.5 KCl, 1 MgCl~2~ and 5 Hepes, pH 7.5) followed by three washing steps and storage at 16°C in Barth solution (in mM: 88 NaCl, 2.4 NaHCO~3~, 1 KCl, 0.33 Ca(NO~3~)~2~, 0.41 CaCl~2~, 0.82 MgSO~4~ and 5 Tris/HCl, pH 7.4 with NaOH) supplemented with 50 μg/ml gentamicin (Biochrm KG). 50 nl of cRNA encoding wildtype (WT) or mutated K~V~1.2 subunits (1μg/μl) was injected into oocytes using the Roboocyte2 (Multi Channel Systems, Reutlingen, Germany) and stored for two days (at 17°C) prior to the experiment. Amplitudes of currents of WT and mutant channels recorded on the same day were normalized to the mean value of the 1.0 K~V~1.2 WT on that day to pool the normalized data from different experiments together.

### Automated two-electrode voltage-clamp {#S10}

Potassium currents in oocytes were recorded at room temperature (20-22°C) using Roboocyte2 (Multi channel Systems, Reutlingen, Germany). For two-electrode voltage-clamp (TEVC) recordings, oocytes were impaled with two glass electrodes with a resistance of 0.4 -- 1 MΩ containing 1 M KCl/ 1.5 M KAc and clamped at a holding potential of −80 mV. Oocytes were perfused with a ND96 bath solution containing (in mM): 93.5 NaCl, 2 KCl, 1.8 CaCl~2~, 2 MgCl~2~, 5 HEPES (pH 7.6). Currents were sampled at 5 kHz.

### Voltage clamp protocols and data analysis {#S11}

The membrane was depolarized to various test potentials from a holding potential of −80 mV to record potassium currents. The activation curve (conductance--voltage relationship) was derived from the current--voltage relationship that was obtained by measuring the peak current at various step depolarizations from the holding potential of −80 mV (10 mV increment, depolarized to +70 mV). The following Boltzmann function was fitted to the obtained data points: $$g\left( V \right) = \frac{g_{\max}}{\left\{ {1 + \exp\left\lbrack \left( V - V_{1 \slash 2} \right)\slash k_{v} \right\rbrack} \right\}}$$ with g (V) = I/(V-V~rev~) being the conductance, I the recorded current amplitude at test potential V, V~rev~ the potassium reversal potential, g~max~ the maximal conductance, V~1/2~ the voltage of half-maximal activation and k~V~ a slope factor. Voltage-dependent inactivation of WT and mutated K~V~1.2 channels were analyzed using 25-s conditioning pulses at potentials ranging −60 mV to 0 mV (increment 10 mV) from a holding of −80 mV, the test pulse was 30 mV. A standard Boltzmann function was fitted to the inactivation curves: $$I\left( V \right) = \frac{I_{\max}}{\left\{ {1 + \exp\left\lbrack \left( V - V_{1 \slash 2} \right)\slash k_{v} \right\rbrack} \right\}}$$ with I being the recorded current amplitude at the conditioning potential V, I~max~ being the maximal current amplitude, V~1/2~ the voltage of half-maximal inactivation, and k~V~ a slope factor.

### Western Blot Analysis {#S12}

For Western blot, injected *Xenopus* oocytes were lysed in a buffer containing (in mM) 20 Tris, 100 NaCl, 1 ethylenediaminetetraacid, 0.5% Triton X-100 and 10% glycerol with protease inhibitor cOmplete (Roche, Basel, Switzerland). In addition, for the P405L mutation CHO cells were transfected with 10 μg/μl DNA using Mirus "TransIT®-LT1" reagent. CHO cells were lysed in a buffer containing (in M): 2 Tris (pH 7.5), 3 NaCl, 0.2 EDTA, 0.2 EGTA, 0.25 Napyrophosphate, 0.1 β-glycerolphosphate, 0.1 sodium-orthovanadate, 1 DTT, 0.1 1% Triton and 25x cOmplete solution (Roche). For measuring protein concentrations (BCA systems, Thermo Fisher Scientific) 15 -- 20 μg of protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS Page) on 8% polyacrylamide gels. The proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (PALL Corporation, Port Washington, NY), and Western blotting was performed using a mouse-Anti-K~V~1.2 antibody (NeuroMab clone K14/16). Water-injected oocytes, untransfected (u.t.) and water transfected (Mock) CHO cells were used as controls.

### Data and statistical analysis {#S13}

Sample size was estimated by using GraphPad StatMate Software. TEVC recordings were analyzed using Roboocyte 2+ (Multi Channel Systems, Germany) and Clampfit (pClamp, Axon Instruments), Origin 6.1 (Origin-Lab Corp., Northampton, USA), and Excel (Microsoft, USA) software. Data were tested for normal distribution using SigmaPlot12 (Systat Software). For statistical evaluation one-way ANOVA with Dunnett's posthoc test (normally distributed data) or one-way ANOVA on ranks with Dunn's posthoc test (not-normally distributed data) was used for comparing multiple groups, with one-way ANOVA testing the overall difference between groups and posthoc tests telling the difference between specific groups. For unpaired data sets Student's t-test (normally distributed unpaired data sets) or Mann-Whitney rank-sum (not-normally distributed) were used. All data are shown as mean ± SEM. For all statistical tests, significance with respect to control is indicated in the figures using the following symbols: \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.
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![Mutations in the K~V~1.2 channel. **(A)** Structure of the voltage-gated potassium channel K~V~1.2 with transmembrane segments S1--S4 forming the voltage sensor domain (light gray) and the pore region S5-S6 (in dark gray) with its pore-forming loop. Mutations are localized in highly-conserved regions in the S3 segment (I263T, light blue), the S4 segment constituting the voltage sensor (R297Q, red; L298F, orange) and the S6 segment (P405L, dark blue). **(B)** I263, R297, L298 and P405 and the respective surrounding amino acids show evolutionary conservation. **(C)** Pedigrees of patients \#1, \#2 and \#4--7.](emss-62156-f0001){#F1}

![Functional effects of the *KCNA2* mutations P405L and I263T. **(A)** Representative current traces of K~V~1.2 wildtype (WT) channels recorded in a *Xenopus laevis* oocyte during voltage steps (from −80 mV to +70 mV). **(B)** Effect of increasing amounts of injected WT-*KCNA2* cRNA on current amplitude (0.25: n=13; 0.5: n=18; 1: n=22; 2: n=17; 4: n=20; 8: n=19). Shown are means ± SEM. **(C)** Current traces derived from K~V~1.2-P405L (top) and K~V~1.2-I263T (bottom) channels recorded as described in (A). **(D)** K^+^-currents were reduced for mutants P405L (top) and I263T (bottom) compared to WT-cRNA (top: P405L: n=10; WT: n=44; bottom: I263T: n=10; WT: n=34). A dominant-negative effect of P405L and I263T mutants on K~V~1.2-WT channels was shown when a constant amount of WT cRNA (amount 1 in (B)) was injected with either H~2~O or increasing amounts of mutant cRNA (top: P405L: ratio 1:1: n=47; ratio 1:2: n=40; ratio 1:4: n=36; bottom: I263T: ratio 1:1: n=34; ratio 1:2: n=42; ratio 1:4: n=38). Co-expression of P405L or I263T and the WT led to a significant reduction of the current amplitude compared to the WT alone. Groups were statistically different (One-way ANOVA (p\<0.001), posthoc Dunn's method (p\<0.05)). Shown are means ± SEM. **(E)** Western blot analysis from lysates of *Xenopus laevis* oocytes injected with equal amounts of K~V~1.2-WT or mutant cRNA (P405L: top; I263T: bottom) or from lysates of CHO cells transiently transfected with K~V~1.2-WT and P405L cDNAs (middle). For P405L-mutant channels there was a shift from 57 kDa to \~58.5 kDa (n=3). K~V~1.2-WT or I263T (n=3) mutant channels revealed similar bands (57 kDa).](emss-62156-f0002){#F2}

![Functional effects of the K~V~1.2 mutations R297Q and L298F. **(A)** Representative current traces derived from K~V~1.2-WT (top), R297Q (middle) or L298F mutant channels (bottom) recorded as described in [Fig. 2A](#F2){ref-type="fig"}. **(B)** Mean current amplitudes of [top:]{.ul} K~V~1.2-WT (1.0, n=23), WT + R297Q (0.5:0.5, n=37), R297Q (1.0, n=35) and H~2~O injection (n=25); [bottom:]{.ul} K~V~1.2-WT (1.0, n=13), WT + L298F (0.5:0.5, n=26), L298F (1.0, n=14), and H~2~O injection (n=10). Shown are means±SEM. There was a statistical significant difference between WT and tested groups (ANOVA on ranks; p\<0.001) with posthoc Dunn's Method (p\<0.05)). **(C)** Mean voltage dependence of K~V~1.2 channel activation for WT, R297Q (red, top) or L298F channels (orange, bottom). Shown are means ± SEM. Lines represent Boltzmann functions fit to data points. Activation curves of mutant channels were significantly shifted to more hyperpolarized potentials (p\<0.05). For details see [Supplementary notes](#SD1){ref-type="supplementary-material"}. **(D)** Resting membrane potentials of oocytes injected with: [top:]{.ul} WT (1.0, n=44), WT+R297Q (0.5:0.5, n=42), R297Q (1.0; n=38) or H~2~O (n=24); [bottom:]{.ul} WT (1.0, n=30), WT+L298F (0.5:0.5, n=34), L298F (1.0; n=28) or H~2~O (n=13). Shown are means ± SEM. Statistically significant differences between WT and tested groups was verified by ANOVA on ranks (p\<0.001) with posthoc Dunn's Method (p\<0.05). **(E)** Western blot analysis from lysates of *Xenopus* oocytes injected with K~V~1.2-WT (1.0), K~V~1.2-WT (0.5) + R297Q (0.5, top), mutant R297Q (1.0, top), K~V~1.2-WT (0.5) + L298F (0.5, bottom) or mutant L298F (1.0, bottom) cRNA (n=3). All channels revealed similar bands (57 kDa).](emss-62156-f0003){#F3}

###### 

Main phenotypic characteristics of patients carrying a disease-causing *de novo KCNA2* mutation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           **Patient 1**                                                                                                                        **Patient 2**                             **Patient 4**                                                                                                                                                                         **Patient 5**                                                       **Patient 6**                                                                                 **Patient 7**
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------
  **Cohort**                               1^st^ epilepsy panel (n=33)                                                                                                          MAE (n=39)                                DS (n=31)                                                                                                                                                                             adult EE I (n=147)                                                  adult EE II (n=10)                                                                            Ataxia & epilepsy (n=12)

  **Mutation**                             c.1214C\>T, p.Pro405Leu *de novo*                                                                                                    c.788T\>C, p.Ile263Thr *de novo*          c.1214C\>T, p.Pro405Leu *de novo*                                                                                                                                                     c.1214C\>T, p.Pro405Leu *de novo*                                   c.894G\>T, p.Leu298Phe *de novo*                                                              c.890G\>A, p.Arg297Gln *de novo*

  **Functional consequence**               loss of function                                                                                                                     gain of function                                                                                                                                                                                                                                                                                                                                                                                  

  **Gender/Age**                           F/8y                                                                                                                                 M/7y                                      F/5y                                                                                                                                                                                  M/19y                                                               M/36y                                                                                         M/26y

  **Development prior to seizure onset**   normal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Age at seizure onset**                 17m                                                                                                                                  11m                                       10m                                                                                                                                                                                   8m                                                                  6m                                                                                            5m

  **Seizure type at onset**                FS, hemiclonic seizures                                                                                                              MC                                        FS, FDS                                                                                                                                                                               Febrile SE                                                          GTCS                                                                                          Febrile SE

  **Other seizure types**                  FS, MC, FDS, focal motor seizures, secondary GTCS                                                                                    MC, MA                                    FS, FDS, focal motor seizures, possible extension spasms                                                                                                                              FS, focal motor seizures, secondary GTCS                            MC, atypical absences                                                                         GTCS, absences

  **Seizure outcome**                      Seizure free since age 7 ½y old                                                                                                      Seizure free since age 4y old             Seizure free since age 4y old                                                                                                                                                         Seizure free since age 15y old                                      GTCS bimonthly on polytherapy                                                                 GTCS once a year on lamotrigine

  **EEG at onset**                         Focal sharp waves                                                                                                                    Focal sharp waves and spikes              normal                                                                                                                                                                                Sharp waves, bilateral centro-temporo-frontal spikes                n.a.                                                                                          n.a.

  **Course of EEG**                        Multifocal sharp waves and sharp slow waves, accentuated over the left frontocentral region with significant increase during sleep   Multifocal sharp waves and polyspikes.\   Focal sharp waves.\                                                                                                                                                                   At age 4y: multifocal epileptiform discharges activated by sleep\   At age 22y: frequent generalized spike wave discharges in a diffusely slow background         At age 6y: generalized spike waves and polyspike-waves
                                                                                                                                                                                Since age 6y: normal                      From age 2y: sharp waves, spike-waves and polyspike-waves over both centro-temporal regions, independently or bilaterally synchronous (left more than right); increase during sleep   Since age 17y: normal                                                                                                                                             

  **Neurological examination**             Mild-moderate ataxia, constant myoclonus                                                                                             normal                                    Mild ataxia, myoclonus at rest in hand and fingers                                                                                                                                    normal                                                              Moderate ataxia, occasional myoclonus at rest                                                 Moderate-severe ataxia, hyperreflexia

  **Development at last follow up**        Mild-moderate ID, delayed speech development                                                                                         Mild-moderate ID                          Learning disability, delayed speech development                                                                                                                                       Moderate ID, delayed speech development                             Severe ID, no speech, requires help with all aspects of daily activities                      Moderate ID

  **MRI**                                  normal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Additional features**                  GH deficiency, IGF-1: −0.7 SDS (1y2m), −8.5 SDS (3y5m) subclinical hypothyroidism                                                                                                                                                                                                                                                                                    Severe scoliosis                                                    Facial dysmorphism (broad forehead, bulbous nasal tip, deep set eyes, synophris, full lips)   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: F: female; FDS: focal dyscognitive seizures; FS: febrile seizures; GH: growth hormone; GTCS: generalized tonic-clonic seizures; ID: intellectual disability; HC: head circumference; m: months; M: male; MA: myoclonic-atonic seizures; MC: myoclonic seizures; n.a.: not available; SE: status epilepticus; y: years
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